Jordanian researchers secure US patent for promising cancer treatment formula

A research team from the Faculty of Science at Yarmouk University has secured a US patent for innovative pharmaceutical compounds designed to treat cancer.

The patent, titled “Pharmaceutical Compositions Derived from Benzoxazepine for Cancer Treatment" was registered with the United States Patent and Trademark Office (USPTO).

The team, led by Dr. Shehadeh Mzid, included Dr. Khaled Abu Khadra from the Department of Biological Sciences, researcher Huda Al-Saadi, and collaborators Dr. Firas Al-Awadi and Dr. Areej Asaf from the University of Jordan.

According to Dr. Mzid, the patented compounds consist of heterocyclic structures that have demonstrated high efficacy in combating certain types of cancer. The invention outlines the preparation of these compounds and their application as effective treatments by administering precise therapeutic doses.

Dr. Mzid emphasized that the team continues to refine these pharmaceutical formulations to ensure enhanced accuracy and effectiveness.

He highlighted the significant potential of this breakthrough for advancing pharmaceutical industries and applied scientific research, noting that it reflects the high-caliber efforts of Yarmouk University researchers and their commitment to innovation – as reported by the Jordan News Agency (Petra).